Selective growth hormone secretagogue with minimal impact on cortisol and prolactin.
Ghrelin receptor agonist that stimulates pituitary growth hormone release. Highly selective - does not significantly affect cortisol, prolactin, or ACTH levels unlike other GHRPs.
Human pharmacokinetic studies confirm GH release with excellent selectivity. Post-surgical trials show improved nitrogen balance. Generally well-tolerated.
Typically 100-300mcg 2-3x daily, often combined with CJC-1295. Best administered on empty stomach before bed and/or morning.
No documented drug interactions on file.
Not FDA approved. Available through compounding pharmacies with prescription.
Available through compounding pharmacies with valid prescription.
Regulatory data last verified 4/17/2026
Showing 20 of 29 papers. View all on PubMed →